UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A new harmony for hemorrhagic disorders: The Dutch SYMPHONY consortium

Journal of thrombosis and haemostasis, 2022-09, Vol.20 (9), p.1984-1985

Samelson‐Jones, Benjamin J.

2022

Volltextzugriff (PDF)

Haemophilia care: the only constant is change

British journal of haematology, 2021-09, Vol.194 (5), p.805-807

2021

Volltextzugriff (PDF)

Andexanet alfa for reversal of rivaroxaban in a child with intracranial hemorrhage

Pediatric blood & cancer, 2022-06, Vol.69 (6), p.e29484-n/a

2022

Volltextzugriff (PDF)

Digital haemophilia: Insights into the use of social media for haemophilia care, research and advocacy

Haemophilia : the official journal of the World Federation of Hemophilia, 2022-03, Vol.28 (2), p.247-253

2022

Volltextzugriff (PDF)

Real‐world cost estimates of initiating emicizumab in US patients with haemophilia A

Haemophilia : the official journal of the World Federation of Hemophilia, 2021-07, Vol.27 (4), p.591-598

2021

Volltextzugriff (PDF)

Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX‐Padua

Journal of thrombosis and haemostasis, 2021-05, Vol.19 (5), p.1212-1218

2021

Volltextzugriff (PDF)

Comment on: Bivalirudin during thrombolysis with catheter‐directed tPA in a heparin‐refractory patient: A case report

Pediatric blood & cancer, 2020-12, Vol.67 (12), p.e28518-n/a

2020

Volltextzugriff (PDF)

Adeno-Associated Virus Gene Therapy for Hemophilia

Annual review of medicine, 2023-01, Vol.74 (1), p.231-247

2023

Volltextzugriff (PDF)

Novel approaches to hemophilia therapy: successes and challenges

Blood, 2017-11, Vol.130 (21), p.2251-2256

2017

Volltextzugriff (PDF)

Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B

Molecular therapy, 2020-09, Vol.28 (9), p.2073-2082

2020

Volltextzugriff (PDF)

MYH9‐macrothrombocytopenia caused by a novel variant (E1421K) initially presenting as apparent neonatal alloimmune thrombocytopenia

Pediatric blood & cancer, 2018-04, Vol.65 (4), p.n/a

2018

Volltextzugriff (PDF)

Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A

Frontiers in immunology, 2020-04, Vol.11, p.618-618

2020

Volltextzugriff (PDF)

Activated protein C has a regulatory role in factor VIII function

Blood, 2021-05, Vol.137 (18), p.2532-2543

2021

Volltextzugriff (PDF)

Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy

Molecular therapy. Methods & clinical development, 2019-03, Vol.12, p.184-201

2019

Volltextzugriff (PDF)

Worldwide use of factor IX Padua for hemophilia B gene therapy

Molecular therapy, 2022-07, Vol.30 (7), p.2394-2396

Samelson-Jones, Benjamin J.

2022

Volltextzugriff (PDF)

Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates

Molecular therapy. Methods & clinical development, 2020-06, Vol.17, p.1129-1138

2020

Volltextzugriff (PDF)

Immune tolerance induction by hepatic gene transfer: First-in-human evidence

Molecular therapy, 2024-04, Vol.32 (4), p.863-864

2024

Volltextzugriff (PDF)

Coagulation Factor VIII: Biological Basis of Emerging Hemophilia A Therapies

Blood, 2024-08

2024

Volltextzugriff (PDF)

Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A

The New England journal of medicine, 2021-11, Vol.385 (21), p.1961-1973

2021

Volltextzugriff (PDF)

AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life

Molecular therapy. Methods & clinical development, 2024-03, Vol.32 (1), p.101205-101205, Article 101205

2024

Volltextzugriff (PDF)

Emerging therapies for hemophilia: controversies and unanswered questions

F1000 research, 2018, Vol.7, p.489

2018

Volltextzugriff (PDF)

Analysis of vector genome integrations in multicentric lymphoma after AAV gene therapy in a severe hemophilia A dog

Molecular therapy. Methods & clinical development, 2023-12, Vol.31, p.101159-101159, Article 101159

2023

Volltextzugriff (PDF)

Gene Therapy for Inherited Bleeding Disorders

Seminars in thrombosis and hemostasis, 2021-03, Vol.47 (2), p.161-173

2021

Volltextzugriff (PDF)

IVIG-Associated Maternal Pancytopenia during Treatment for Neonatal Alloimmune Thrombocytopenia

American journal of perinatology reports, 2017-07, Vol.7 (3), p.e197-e200

2017

Volltextzugriff (PDF)

Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model

Blood advances, 2018-03, Vol.2 (5), p.505-508

2018

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(42)
Berichte
(1)

Sprache

Englisch
(43)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

A new harmony for hemorrhagic disorders: The Dutch SYMPHONY consortium

Haemophilia care: the only constant is change

Andexanet alfa for reversal of rivaroxaban in a child with intracranial hemorrhage

Digital haemophilia: Insights into the use of social media for haemophilia care, research and advocacy

Real‐world cost estimates of initiating emicizumab in US patients with haemophilia A

Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX‐Padua

Comment on: Bivalirudin during thrombolysis with catheter‐directed tPA in a heparin‐refractory patient: A case report

Adeno-Associated Virus Gene Therapy for Hemophilia

Novel approaches to hemophilia therapy: successes and challenges

Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B

MYH9‐macrothrombocytopenia caused by a novel variant (E1421K) initially presenting as apparent neonatal alloimmune thrombocytopenia

Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A

Activated protein C has a regulatory role in factor VIII function

Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy

Worldwide use of factor IX Padua for hemophilia B gene therapy

Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates

Immune tolerance induction by hepatic gene transfer: First-in-human evidence

Coagulation Factor VIII: Biological Basis of Emerging Hemophilia A Therapies

Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A

AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life

Emerging therapies for hemophilia: controversies and unanswered questions

Analysis of vector genome integrations in multicentric lymphoma after AAV gene therapy in a severe hemophilia A dog

Gene Therapy for Inherited Bleeding Disorders

IVIG-Associated Maternal Pancytopenia during Treatment for Neonatal Alloimmune Thrombocytopenia

Complete correction of hemophilia B phenotype by FIX-Padua skeletal muscle gene therapy in an inhibitor-prone dog model

Suchergebnisse filtern